J&J Risperdal Consta Priced Comparable To Zyprexa; Clears FDA Oct. 29
Executive Summary
Johnson & Johnson has room to price its long-acting risperidone injection Risperdal Consta 40% higher than Risperdal tablets, while still remaining comparable to Lilly's Zyprexa
You may also be interested in...
FDA Approves Zyprexa IM; Milestone In Lilly GMP Turnaround
Lilly's Zyprexa IM has cleared FDA three years after a pre-approval inspection for the intramuscular antipsychotic triggered a period of Good Manufacturing Practices compliance issues for the company
FDA Approves Zyprexa IM; Milestone In Lilly GMP Turnaround
Lilly's Zyprexa IM has cleared FDA three years after a pre-approval inspection for the intramuscular antipsychotic triggered a period of Good Manufacturing Practices compliance issues for the company
Risperdal Consta Priced Aggressively; J&J Sets High Premium To Zyprexa
Johnson & Johnson's Risperdal Consta (risperidone) is being launched at approximately twice the daily cost of Lilly's market-leading antipsychotic Zyprexa (olanzapine)